Logo
  • Home
  • AI Agent
  • Annotations
  • Files
  • Pricing and plans
  • BlogAboutContact us
    APIMCP
    Terms of servicePrivacy policy
  • Get the full experience

    We save the real magic for signed-in users.

ZBH US​
HomeStock ScreenerDocument SearchChartingWatchlistsRecent Filings
Logo
  • Home
  • AI Agent
  • Annotations
  • Files
  • Pricing and plans
  • BlogAboutContact us
    APIMCP
    Terms of servicePrivacy policy
  • Get the full experience

    We save the real magic for signed-in users.

ZBH US​
HomeStock ScreenerDocument SearchChartingWatchlistsRecent Filings

Zimmer Biomet Holdings Inc.(ZBH US)

$104.56-2.912.71%Ext:$98.90-5.665.42%(Market Closed · 01:00:02 UTC)
Ask AI
Doc SearchProfileEntity StructureEDINET FilingsFinancialsChartingShort InterestEmployees

Overview

ProfileEntity Structure

Documents

SEC Filings

Zimmer Biomet Holdings Inc.(ZBH US)

$104.56-2.912.71%Ext:$98.90-5.665.42%(Market Closed · 01:00:02 UTC)
Ask AI
Doc SearchProfileEntity StructureEDINET FilingsFinancialsChartingShort InterestEmployees

Overview

ProfileEntity Structure

Documents

SEC Filings
EDINET Filings

Financials & Metrics

FinancialsChartingShort InterestEmployees
EDINET Filings

Financials & Metrics

FinancialsChartingShort InterestEmployees

Zimmer Biomet Holdings Inc. — Company Profile

Zimmer Biomet Holdings, Inc. engages in the design, manufacture, and marketing of orthopedic reconstructive products. The firm also offers sports medicine, biologics, extremities, and trauma products, spine, craniomaxillofacial, and thoracic products, office-based technologies, dental implants, and related surgical products. It operates through the following geographical segments: Americas, Europe Middle East and Africa, and Asia Pacific. The Americas segment consists of the U.S. and includes other North, Central and South American markets. The Europe Middle East and Africa segment includes France, Germany, Italy, Spain, and the United Kingdom. The Asia Pacific segment refers to the key markets such as Japan, China, Australia, New Zealand, Korea, Taiwan, India, Thailand, Singapore, Hong Kong, and Malaysia. The company was founded by Justin O. Zimmer in 1927 and is headquartered in Warsaw, IN.

Sector
Materials
Industry
Paper & Forest Products
Exchange
UN
CEO
Ivan Tornos
Headquarters
Warsaw, IN, US
IPO Date
Jul 25, 2001
Employees
17,000
Website
www.zimmerbiomet.com

Key Metrics

Price
$88.29
Market Cap
$17.08B
Revenue (TTM)
$2.09B
Net Income (TTM)
$238.10M
EPS (TTM)
1.22
P/E (TTM)
22.44
P/B (TTM)
1.35
Dividend Yield
116.60%
ROE (TTM)
1.88%
ROA (TTM)
1.05%
Operating Margin
17.88%
Beta
0.17

Dividends

Last Dividend
$0.24
Last Yield
1.17%

Summary

Zimmer Biomet Holdings, Inc. engages in the design, manufacture, and marketing of orthopedic reconstructive products. The firm also offers sports medicine, biologics, extremities, and trauma products, spine, craniomaxillofacial, and thoracic products, office-based technologies, dental implants, and related surgical products. It operates through the following geographical segments: Americas, Europe Middle East and Africa, and Asia Pacific. The Americas segment consists of the U.S. and includes other North, Central and South American markets. The Europe Middle East and Africa segment includes France, Germany, Italy, Spain, and the United Kingdom. The Asia Pacific segment refers to the key markets such as Japan, China, Australia, New Zealand, Korea, Taiwan, India, Thailand, Singapore, Hong Kong, and Malaysia. The company was founded by Justin O. Zimmer in 1927 and is headquartered in Warsaw, IN.

Website
www.zimmerbiomet.com
Location
Warsaw, IN, US
Phone574 267 6131
Employees17,000
CEOIvan Tornos
Sector
Materials
Industry
Paper & Forest Products
IPO DateJul 25, 2001

Ask AI

Company overview
Business model, segments, and competition.
Peer comparison
Metrics vs closest competitors.
Guidance & outlook
Forward guidance and assumptions.
Bull vs bear case
Upside drivers and key risks.
Valuation snapshot
Multiples vs history and peers.
Competitive moat
Defensibility and market position.
Management track record
Leadership and capital allocation history.
How it makes money
A short diagram of the business model.

Latest Documents

SEC Filings(2.6K)

Expand
  • CERTCERT13 Nov
  • 8-A12BRegistration of securities (Section 12(b))12 Nov
  • 8-KEntry into a Material Definitive Agreement12 Nov
  • 424B5Prospectus filing (Rule 424(b)(5))9 Nov
  • 424B5Prospectus filing (Rule 424(b)(5))9 Nov
  • FWPFree writing prospectus5 Nov
  • FWPFree writing prospectus5 Nov
  • 424B5Prospectus filing (Rule 424(b)(5))5 Nov
  • 424B5Prospectus filing (Rule 424(b)(5))5 Nov
  • 10-QQ3ended 30 Sept 20264 Nov
  • 8-KResults of Operations and Financial Condition4 Nov
  • Form 4Campbell Gary Craig5 Oct
  • Form 3Hatcher Brian Matthew5 Oct
  • Form 3Campbell Gary Craig5 Oct
  • Form 4Farrell Michael J.2 Oct
  • Form 4HAGEMANN ROBERT2 Oct
  • Form 4HIGGINS ARTHUR J2 Oct
  • Form 4Shapiro Louis2 Oct
  • Form 4Hilado Maria Teresa2 Oct
  • Form 4Kurdikar Devdatt2 Oct

EDINET Filings(29)

Expand
  • IRSemi-Annual Report (2026.01.01-2026.12.31)24 Sep
  • 10-KAmended Annual Securities Report10 Sep
  • IRExtraordinary Report1 Jun
  • 10-KAnnual Securities Report (2025.01.01-2025.12.31)23 Apr
  • IRExtraordinary Report4 Feb
  • IRExtraordinary Report11 Nov 2025
  • IRSemi-Annual Report (2025.01.01-2025.12.31)24 Sep 2025
  • PRSSecurities registration statement22 May 2025
  • 10-KAnnual Securities Report (2024.01.01-2024.12.31)24 Apr 2025
  • IRExtraordinary Report31 Mar 2025
  • PRSSecurities registration statement21 Nov 2024
  • IRSemi-Annual Report (2024.01.01-2024.12.31)25 Sep 2024
  • 10-KAmended Annual Securities Report11 Sep 2024
  • PRSSecurities registration statement23 May 2024
  • 10-KAnnual Securities Report (2023.01.01-2023.12.31)25 Apr 2024
  • PRSSecurities registration statement22 Nov 2023
  • PRSSecurities registration statement24 May 2022
  • 10-KAnnual Securities Report (2021.01.01-2021.12.31)28 Apr 2022
  • PRSSecurities registration statement1 Mar 2022
  • PRSSecurities registration statement22 Nov 2021

News

  • Financial Contrast: Zimmer Biomet (NYSE:ZBH) and Artivion (NYSE:AORT)11 Nov
  • Best Stocks for 2027: 3 Experts Name Their Top Picks11 Nov
  • Zimmer Biomet to Present at the Annual Jefferies Global Healthcare Conference in London9 Nov
  • What Zimmer Biomet (ZBH) Said on Its Q3 Earnings Call8 Nov
  • Zimmer Biomet Introduces Surgeon-Guided Autonomy, a New Category in Intelligent Surgery6 Nov
  • Why Zimmer Biomet (ZBH) is a Top Momentum Stock for the Long-Term5 Nov
  • Zimmer Biomet Lifts Annual Growth Despite Challenging Knee Market4 Nov
  • Zimmer Biomet Holdings, Inc. (ZBH) Q3 2026 Earnings Call Transcript4 Nov
  • Zimmer Biomet Stock Up on Q3 Earnings & Revenue Beat, '26 View Up4 Nov
  • Zimmer (ZBH) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates4 Nov
  • Zimmer Biomet (ZBH) Q3 Earnings and Revenues Beat Estimates4 Nov
  • Zimmer Biomet Announces Third Quarter 2026 Financial Results4 Nov
  • Zimmer Biomet Gears Up to Report Q3 Earnings: What's in the Cards?29 Oct
  • Why Zimmer Biomet (ZBH) is a Top Value Stock for the Long-Term29 Oct
  • Zimmer Biomet to Preview the Next Era of Intelligent Orthopedic Surgery at AAHKS 202629 Oct
  • ZIMMER BIOMET AND THINK SURGICAL EXTEND EXCLUSIVE DISTRIBUTION AGREEMENT13 Oct
  • Should Value Investors Buy Zimmer Biomet (ZBH) Stock?12 Oct
  • Zimmer Biomet (ZBH) is a Top-Ranked Value Stock: Should You Buy?7 Oct
  • Zimmer Biomet Announces Webcast and Conference Call of Third Quarter 2026 Financial Results6 Oct
  • Critical Review: Zimmer Biomet (NYSE:ZBH) and Butterfly Network (NYSE:BFLY)6 Oct

Mentions in Filings

  • On May 12, 2025, we filed a lawsuit in the United States District Court for the District of Delaware (captioned Treace Medical Concepts, Inc. v. <strong>Zimmer Biomet Holdings, Inc.</strong> et al. Case No. 1:25-cv-00592-CBW) against Zimmer Biomet Holdings, Inc. and Paragon 28, Inc. alleging infringement of four patents related to our innovative Lapiplasty 3D Bunion Correction technologies and seeking injunctive relief and damages. On August 5, 2025, we filed an …
    TREACE MEDICAL CONCEPTS, INC.Zimmer Biomet Holdings Inc.·10-Q - Quarterly report Q3·Q3 26·6 Nov
  • … a handheld cryoanalgesia device that delivers immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve, to Zimmer, Inc., or Zimmer, a subsidiary of <strong>Zimmer Biomet Holdings, Inc.</strong> For more information, see Note 3, iovera° Divestiture. Proposed Acquisition by Viatris Inc. On October 8, 2026, the Company entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Viatris I …
    Pacira BioSciences, Inc.Zimmer Biomet Holdings Inc.·10-Q - Quarterly report Q3·Q3 26·5 Nov
  • … of iovera°, a handheld cryoanalgesia device that delivers immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve, to Zimmer, Inc., a subsidiary of <strong>Zimmer Biomet Holdings, Inc.</strong> 20 --- TABLE OF CONTENTS Available Information. The Shares are registered under the Exchange Act. Accordingly, Pacira is subject to the information reporting requirements of the Exchange Act and, in accorda …
    Pacira BioSciences, Inc.Zimmer Biomet Holdings Inc.·EX-99.(A)(1)(A) - SC TO-T - EXHIBIT (A)(1)(A)·Q4 26·30 Oct
  • … ur investments are recorded at estimated fair value, and the period-to-period valuation can be highly volatile. For example, our investment in Monogram Technologies, Inc. was valued as of September 30, 2025 at the cash price we received in October 2025, upon its acquisition by <strong>Zimmer Biomet Holdings, Inc.</strong> We received $4.04 per share for each of the common shares we owned of Monogram, for a total of $8.9 million in cash proceeds. **CEO Comments**
    PRO DEX INCZimmer Biomet Holdings Inc.·EX-99.1 - 8-K - Results of Operations and Financial Condition·Q2 27·29 Oct
  • … s that, in accordance with our internal policies regarding the approval of related-party transactions, were approved by our then three Board members that are not affiliated with Air T, Inc. On October 7, 2025, <strong>Zimmer Biomet Holdings, Inc.</strong> (“Zimmer Biomet”) announced that it had completed its acquisition of Monogram and soon after the announcement we received $4.04 per share in cash for each of the 2,212,378 common shares we owned of Monogram pri …
    PRO DEX INCZimmer Biomet Holdings Inc.·ARS - Annual report to security holders·FY26·6 Oct
  • … 3% | | 12 | | 197.16 | | 2,366 | | VEEV | Veeva Systems Inc. (Class A) \* | | 0.34% | | 20 | | 306.40 | | 6,128 | | VRTX | Vertex Pharmaceuticals Incorporated \* | | 1.01% | | 33 | | 550.87 | | 18,179 | | ZBH | <strong>Zimmer Biomet Holdings, Inc.</strong> | | 0.13% | | 22 | | 108.33 | | 2,383 | | Industrials (16.57%): | | | | | | | | | | | ADP | Automatic Data Processing, Inc. | | 0.34% | | 20 | | 302.06 | | 6,041 | | BRC | Brady Corporation | | 0.07% | | 15 | | …
    FT 13365Zimmer Biomet Holdings Inc.·487 - Form 487 - FORM S-6 TO EFFECTIVE AMENDMENT·Q4 26·10 Nov

Key Stats

Trading

Px/Chg 1D$88.29 / +0.26%
Avg Volume2.22M
Beta0.17
Mkt Cap17.08B
FD Mkt Cap19.30B

Float

Shrs Out/Float193.46M / 193.11M
Short Float0.06%
Days to Cover4.63
Stock Repurchased$250.10M

Current Valuation

EV24.14B
EV/EBITDA10.94
EV/Sales2.87
P/B1.35
P/S2.03
FCF Yield1.89%
ROE1.88%
ROA1.05%
Current Ratio1.73

Dividend

Cash$0.24
Yield116.60%
Yield (TTM)116.60%

Estimates

P/E22.44
Est P/E0.00
Est EPS1.86
Est PEG0.00

Valuation

Metric5Yr AvgMay '23May '24May '25Apr '26Oct '26
PRICE-BASED RATIOS
Price / Earnings72.28125.7524.3723.01116.5271.74
Price / Sales5.144.193.372.717.248.19
Price / Book Value1.742.422.001.671.281.35
Price / Free Cash Flow28.7427.2721.0218.2024.3152.90
ENTERPRISE VALUE METRICS
Enterprise Value27,709.034,426.330,312.026,480.623,190.524,135.8
Enterprise Value / Sales6.884.964.103.4510.3411.57
Enterprise Value / EBITDA28.8823.0313.6511.7651.0944.84
Enterprise Value / EBIT61.2560.5823.9021.11136.4964.16

Financials

Full Financials
Millions USD5Yr CAGR (%)Dec '21Dec '22Dec '23Dec '24Dec '25
INCOME STATEMENT
Revenue4.8%6,827.36,939.97,394.27,678.68,231.5
Gross Income1%4,866.94,920.45,310.45,487.45,071.9
EBITDA7.7%1,645.11,494.72,220.22,250.92,217.4
EBIT12.3%707.4568.31,268.51,254.61,123.6
Net Income15.1%401.6231.41,024.0903.8705.2
EPS (Diluted)16.8%1.911.104.884.433.55
BALANCE SHEET
Cash & ST Inv11.9%378.1375.7415.8525.5591.9
Total Assets-39.1%23,456.421,066.021,496.921,365.323,091.7
Total Liabilities-95%10,790.09,039.09,008.88,889.110,385.9
Total Shareholder Equity7.3%12,660.712,020.312,480.512,468.112,697.7
CASH FLOW
Net Operating Cash Flow3.1%1,499.21,284.71,581.61,499.41,697.0
Cap Ex10.2%-152.0-217.6-394.5-356.8-224.5
Free Cash Flow2.2%1,347.21,067.11,187.11,142.61,472.5

Enterprise Value Bridge

Millions USD13 Nov '26
Price (As of 13 Nov '26)104.83
Basic Shares193.46
Market Cap20,280.6
Diluted Shares191.40
Fully Diluted Shares Outstanding191.40
Fully Diluted Market Cap20,064.5
+Consolidated Debt7,504.2
−In-the-Money Convertible Debt—
+Capital Leases-
+Operating Leases—
−Cash & Equivalents-399.9
−Short-term Investments-
+Total Preferred-
−In-the-Money Convertible Preferred—
−Investments in Unconsolidated Subs—
+Non-Controlling Interest10.0
+Pension Liabilities—
Enterprise Value27,394.9

Segment data

Revenue

by Products and services

  • Knees44%
  • S E T28%
  • Hips28%

Revenue

by Geography

  • Americas62%
  • E M E A22%
  • Asia Pacific15%

Related companies

Amgen Inc

AMGN US

Gilead Sciences, Inc.

GILD US

Intuitive Surgical Inc

ISRG US

Moderna, Inc.

MRNA US

Argenx Se

ARGX US

Edwards Lifesciences Corporation

EW US

Revolution Medicines, Inc.

RVMD US

Biogen Inc.

BIIB US

BioNTech SE

BNTX US

STERIS plc

STE US

Nordson Corp

NDSN US

Tyson Foods, Inc.

TSN US

Zimmer Biomet Holdings Inc. — Company Profile

Zimmer Biomet Holdings, Inc. engages in the design, manufacture, and marketing of orthopedic reconstructive products. The firm also offers sports medicine, biologics, extremities, and trauma products, spine, craniomaxillofacial, and thoracic products, office-based technologies, dental implants, and related surgical products. It operates through the following geographical segments: Americas, Europe Middle East and Africa, and Asia Pacific. The Americas segment consists of the U.S. and includes other North, Central and South American markets. The Europe Middle East and Africa segment includes France, Germany, Italy, Spain, and the United Kingdom. The Asia Pacific segment refers to the key markets such as Japan, China, Australia, New Zealand, Korea, Taiwan, India, Thailand, Singapore, Hong Kong, and Malaysia. The company was founded by Justin O. Zimmer in 1927 and is headquartered in Warsaw, IN.

Sector
Materials
Industry
Paper & Forest Products
Exchange
UN
CEO
Ivan Tornos
Headquarters
Warsaw, IN, US
IPO Date
Jul 25, 2001
Employees
17,000
Website
www.zimmerbiomet.com

Key Metrics

Price
$88.29
Market Cap
$17.08B
Revenue (TTM)
$2.09B
Net Income (TTM)
$238.10M
EPS (TTM)
1.22
P/E (TTM)
22.44
P/B (TTM)
1.35
Dividend Yield
116.60%
ROE (TTM)
1.88%
ROA (TTM)
1.05%
Operating Margin
17.88%
Beta
0.17

Dividends

Last Dividend
$0.24
Last Yield
1.17%

Summary

Zimmer Biomet Holdings, Inc. engages in the design, manufacture, and marketing of orthopedic reconstructive products. The firm also offers sports medicine, biologics, extremities, and trauma products, spine, craniomaxillofacial, and thoracic products, office-based technologies, dental implants, and related surgical products. It operates through the following geographical segments: Americas, Europe Middle East and Africa, and Asia Pacific. The Americas segment consists of the U.S. and includes other North, Central and South American markets. The Europe Middle East and Africa segment includes France, Germany, Italy, Spain, and the United Kingdom. The Asia Pacific segment refers to the key markets such as Japan, China, Australia, New Zealand, Korea, Taiwan, India, Thailand, Singapore, Hong Kong, and Malaysia. The company was founded by Justin O. Zimmer in 1927 and is headquartered in Warsaw, IN.

Website
www.zimmerbiomet.com
Location
Warsaw, IN, US
Phone574 267 6131
Employees17,000
CEOIvan Tornos
Sector
Materials
Industry
Paper & Forest Products
IPO DateJul 25, 2001

Ask AI

Company overview
Business model, segments, and competition.
Peer comparison
Metrics vs closest competitors.
Guidance & outlook
Forward guidance and assumptions.
Bull vs bear case
Upside drivers and key risks.
Valuation snapshot
Multiples vs history and peers.
Competitive moat
Defensibility and market position.
Management track record
Leadership and capital allocation history.
How it makes money
A short diagram of the business model.

Latest Documents

SEC Filings(2.6K)

Expand
  • CERTCERT13 Nov
  • 8-A12BRegistration of securities (Section 12(b))12 Nov
  • 8-KEntry into a Material Definitive Agreement12 Nov
  • 424B5Prospectus filing (Rule 424(b)(5))9 Nov
  • 424B5Prospectus filing (Rule 424(b)(5))9 Nov
  • FWPFree writing prospectus5 Nov
  • FWPFree writing prospectus5 Nov
  • 424B5Prospectus filing (Rule 424(b)(5))5 Nov
  • 424B5Prospectus filing (Rule 424(b)(5))5 Nov
  • 10-QQ3ended 30 Sept 20264 Nov
  • 8-KResults of Operations and Financial Condition4 Nov
  • Form 4Campbell Gary Craig5 Oct
  • Form 3Hatcher Brian Matthew5 Oct
  • Form 3Campbell Gary Craig5 Oct
  • Form 4Farrell Michael J.2 Oct
  • Form 4HAGEMANN ROBERT2 Oct
  • Form 4HIGGINS ARTHUR J2 Oct
  • Form 4Shapiro Louis2 Oct
  • Form 4Hilado Maria Teresa2 Oct
  • Form 4Kurdikar Devdatt2 Oct

EDINET Filings(29)

Expand
  • IRSemi-Annual Report (2026.01.01-2026.12.31)24 Sep
  • 10-KAmended Annual Securities Report10 Sep
  • IRExtraordinary Report1 Jun
  • 10-KAnnual Securities Report (2025.01.01-2025.12.31)23 Apr
  • IRExtraordinary Report4 Feb
  • IRExtraordinary Report11 Nov 2025
  • IRSemi-Annual Report (2025.01.01-2025.12.31)24 Sep 2025
  • PRSSecurities registration statement22 May 2025
  • 10-KAnnual Securities Report (2024.01.01-2024.12.31)24 Apr 2025
  • IRExtraordinary Report31 Mar 2025
  • PRSSecurities registration statement21 Nov 2024
  • IRSemi-Annual Report (2024.01.01-2024.12.31)25 Sep 2024
  • 10-KAmended Annual Securities Report11 Sep 2024
  • PRSSecurities registration statement23 May 2024
  • 10-KAnnual Securities Report (2023.01.01-2023.12.31)25 Apr 2024
  • PRSSecurities registration statement22 Nov 2023
  • PRSSecurities registration statement24 May 2022
  • 10-KAnnual Securities Report (2021.01.01-2021.12.31)28 Apr 2022
  • PRSSecurities registration statement1 Mar 2022
  • PRSSecurities registration statement22 Nov 2021

News

  • Financial Contrast: Zimmer Biomet (NYSE:ZBH) and Artivion (NYSE:AORT)11 Nov
  • Best Stocks for 2027: 3 Experts Name Their Top Picks11 Nov
  • Zimmer Biomet to Present at the Annual Jefferies Global Healthcare Conference in London9 Nov
  • What Zimmer Biomet (ZBH) Said on Its Q3 Earnings Call8 Nov
  • Zimmer Biomet Introduces Surgeon-Guided Autonomy, a New Category in Intelligent Surgery6 Nov
  • Why Zimmer Biomet (ZBH) is a Top Momentum Stock for the Long-Term5 Nov
  • Zimmer Biomet Lifts Annual Growth Despite Challenging Knee Market4 Nov
  • Zimmer Biomet Holdings, Inc. (ZBH) Q3 2026 Earnings Call Transcript4 Nov
  • Zimmer Biomet Stock Up on Q3 Earnings & Revenue Beat, '26 View Up4 Nov
  • Zimmer (ZBH) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates4 Nov
  • Zimmer Biomet (ZBH) Q3 Earnings and Revenues Beat Estimates4 Nov
  • Zimmer Biomet Announces Third Quarter 2026 Financial Results4 Nov
  • Zimmer Biomet Gears Up to Report Q3 Earnings: What's in the Cards?29 Oct
  • Why Zimmer Biomet (ZBH) is a Top Value Stock for the Long-Term29 Oct
  • Zimmer Biomet to Preview the Next Era of Intelligent Orthopedic Surgery at AAHKS 202629 Oct
  • ZIMMER BIOMET AND THINK SURGICAL EXTEND EXCLUSIVE DISTRIBUTION AGREEMENT13 Oct
  • Should Value Investors Buy Zimmer Biomet (ZBH) Stock?12 Oct
  • Zimmer Biomet (ZBH) is a Top-Ranked Value Stock: Should You Buy?7 Oct
  • Zimmer Biomet Announces Webcast and Conference Call of Third Quarter 2026 Financial Results6 Oct
  • Critical Review: Zimmer Biomet (NYSE:ZBH) and Butterfly Network (NYSE:BFLY)6 Oct

Mentions in Filings

  • On May 12, 2025, we filed a lawsuit in the United States District Court for the District of Delaware (captioned Treace Medical Concepts, Inc. v. <strong>Zimmer Biomet Holdings, Inc.</strong> et al. Case No. 1:25-cv-00592-CBW) against Zimmer Biomet Holdings, Inc. and Paragon 28, Inc. alleging infringement of four patents related to our innovative Lapiplasty 3D Bunion Correction technologies and seeking injunctive relief and damages. On August 5, 2025, we filed an …
    TREACE MEDICAL CONCEPTS, INC.Zimmer Biomet Holdings Inc.·10-Q - Quarterly report Q3·Q3 26·6 Nov
  • … a handheld cryoanalgesia device that delivers immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve, to Zimmer, Inc., or Zimmer, a subsidiary of <strong>Zimmer Biomet Holdings, Inc.</strong> For more information, see Note 3, iovera° Divestiture. Proposed Acquisition by Viatris Inc. On October 8, 2026, the Company entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Viatris I …
    Pacira BioSciences, Inc.Zimmer Biomet Holdings Inc.·10-Q - Quarterly report Q3·Q3 26·5 Nov
  • … of iovera°, a handheld cryoanalgesia device that delivers immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve, to Zimmer, Inc., a subsidiary of <strong>Zimmer Biomet Holdings, Inc.</strong> 20 --- TABLE OF CONTENTS Available Information. The Shares are registered under the Exchange Act. Accordingly, Pacira is subject to the information reporting requirements of the Exchange Act and, in accorda …
    Pacira BioSciences, Inc.Zimmer Biomet Holdings Inc.·EX-99.(A)(1)(A) - SC TO-T - EXHIBIT (A)(1)(A)·Q4 26·30 Oct
  • … ur investments are recorded at estimated fair value, and the period-to-period valuation can be highly volatile. For example, our investment in Monogram Technologies, Inc. was valued as of September 30, 2025 at the cash price we received in October 2025, upon its acquisition by <strong>Zimmer Biomet Holdings, Inc.</strong> We received $4.04 per share for each of the common shares we owned of Monogram, for a total of $8.9 million in cash proceeds. **CEO Comments**
    PRO DEX INCZimmer Biomet Holdings Inc.·EX-99.1 - 8-K - Results of Operations and Financial Condition·Q2 27·29 Oct
  • … s that, in accordance with our internal policies regarding the approval of related-party transactions, were approved by our then three Board members that are not affiliated with Air T, Inc. On October 7, 2025, <strong>Zimmer Biomet Holdings, Inc.</strong> (“Zimmer Biomet”) announced that it had completed its acquisition of Monogram and soon after the announcement we received $4.04 per share in cash for each of the 2,212,378 common shares we owned of Monogram pri …
    PRO DEX INCZimmer Biomet Holdings Inc.·ARS - Annual report to security holders·FY26·6 Oct
  • … 3% | | 12 | | 197.16 | | 2,366 | | VEEV | Veeva Systems Inc. (Class A) \* | | 0.34% | | 20 | | 306.40 | | 6,128 | | VRTX | Vertex Pharmaceuticals Incorporated \* | | 1.01% | | 33 | | 550.87 | | 18,179 | | ZBH | <strong>Zimmer Biomet Holdings, Inc.</strong> | | 0.13% | | 22 | | 108.33 | | 2,383 | | Industrials (16.57%): | | | | | | | | | | | ADP | Automatic Data Processing, Inc. | | 0.34% | | 20 | | 302.06 | | 6,041 | | BRC | Brady Corporation | | 0.07% | | 15 | | …
    FT 13365Zimmer Biomet Holdings Inc.·487 - Form 487 - FORM S-6 TO EFFECTIVE AMENDMENT·Q4 26·10 Nov

Key Stats

Trading

Px/Chg 1D$88.29 / +0.26%
Avg Volume2.22M
Beta0.17
Mkt Cap17.08B
FD Mkt Cap19.30B

Float

Shrs Out/Float193.46M / 193.11M
Short Float0.06%
Days to Cover4.63
Stock Repurchased$250.10M

Current Valuation

EV24.14B
EV/EBITDA10.94
EV/Sales2.87
P/B1.35
P/S2.03
FCF Yield1.89%
ROE1.88%
ROA1.05%
Current Ratio1.73

Dividend

Cash$0.24
Yield116.60%
Yield (TTM)116.60%

Estimates

P/E22.44
Est P/E0.00
Est EPS1.86
Est PEG0.00

Valuation

Metric5Yr AvgMay '23May '24May '25Apr '26Oct '26
PRICE-BASED RATIOS
Price / Earnings72.28125.7524.3723.01116.5271.74
Price / Sales5.144.193.372.717.248.19
Price / Book Value1.742.422.001.671.281.35
Price / Free Cash Flow28.7427.2721.0218.2024.3152.90
ENTERPRISE VALUE METRICS
Enterprise Value27,709.034,426.330,312.026,480.623,190.524,135.8
Enterprise Value / Sales6.884.964.103.4510.3411.57
Enterprise Value / EBITDA28.8823.0313.6511.7651.0944.84
Enterprise Value / EBIT61.2560.5823.9021.11136.4964.16

Financials

Full Financials
Millions USD5Yr CAGR (%)Dec '21Dec '22Dec '23Dec '24Dec '25
INCOME STATEMENT
Revenue4.8%6,827.36,939.97,394.27,678.68,231.5
Gross Income1%4,866.94,920.45,310.45,487.45,071.9
EBITDA7.7%1,645.11,494.72,220.22,250.92,217.4
EBIT12.3%707.4568.31,268.51,254.61,123.6
Net Income15.1%401.6231.41,024.0903.8705.2
EPS (Diluted)16.8%1.911.104.884.433.55
BALANCE SHEET
Cash & ST Inv11.9%378.1375.7415.8525.5591.9
Total Assets-39.1%23,456.421,066.021,496.921,365.323,091.7
Total Liabilities-95%10,790.09,039.09,008.88,889.110,385.9
Total Shareholder Equity7.3%12,660.712,020.312,480.512,468.112,697.7
CASH FLOW
Net Operating Cash Flow3.1%1,499.21,284.71,581.61,499.41,697.0
Cap Ex10.2%-152.0-217.6-394.5-356.8-224.5
Free Cash Flow2.2%1,347.21,067.11,187.11,142.61,472.5

Enterprise Value Bridge

Millions USD13 Nov '26
Price (As of 13 Nov '26)104.83
Basic Shares193.46
Market Cap20,280.6
Diluted Shares191.40
Fully Diluted Shares Outstanding191.40
Fully Diluted Market Cap20,064.5
+Consolidated Debt7,504.2
−In-the-Money Convertible Debt—
+Capital Leases-
+Operating Leases—
−Cash & Equivalents-399.9
−Short-term Investments-
+Total Preferred-
−In-the-Money Convertible Preferred—
−Investments in Unconsolidated Subs—
+Non-Controlling Interest10.0
+Pension Liabilities—
Enterprise Value27,394.9

Segment data

Revenue

by Products and services

  • Knees44%
  • S E T28%
  • Hips28%

Revenue

by Geography

  • Americas62%
  • E M E A22%
  • Asia Pacific15%

Related companies

Amgen Inc

AMGN US

Gilead Sciences, Inc.

GILD US

Intuitive Surgical Inc

ISRG US

Moderna, Inc.

MRNA US

Argenx Se

ARGX US

Edwards Lifesciences Corporation

EW US

Revolution Medicines, Inc.

RVMD US

Biogen Inc.

BIIB US

BioNTech SE

BNTX US

STERIS plc

STE US

Nordson Corp

NDSN US

Tyson Foods, Inc.

TSN US